Sugi Predict

Sugi Predict / Compounds / SCHEMBL2915017

SCHEMBL2915017

SCHEMBL2915017

CC(=O)c1ccc(C2OCCn3cncc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 1/20 0.42
▸ CYP19A1 P11511 1/20 0.39
▸ RIPK1 Q13546 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP1A1 P04798 1/20 0.36
▸ KCNJ1 P48048 2/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ BAZ2B Q9UIF8 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ ATM Q13315 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27759827 0.86 RIPK1 (0.47) CYP17A1CYP19A1RIPK1SMN1; SMN2HRH3
SCHEMBL14401657 0.80 CYP17A1 (0.33) CYP17A1RIPK1
SCHEMBL2944559 0.80 GPR119 (0.35) CYP17A1RIPK1PTGS2
SCHEMBL1181751 0.77 CYP17A1 (0.62) CYP17A1CYP19A1RIPK1SMN1; SMN2KCNJ1
SCHEMBL2915311 0.65 SLC6A4 (0.40) SMN1; SMN2DRD2MAPTALDH1A1ATM
SCHEMBL25951392 0.64 CYP17A1 (0.32) CYP17A1
SCHEMBL4836281 0.64 DRD3 (0.43) CYP19A1LMNASMN1; SMN2CYP1A1HRH3
SCHEMBL27723960 0.64 CYP17A1 (0.58) CYP17A1CYP19A1RIPK1LMNASMN1; SMN2
SCHEMBL1429353 0.64 SMN1; SMN2 (0.56) LMNASMN1; SMN2CYP1A1MEN1KMT2A
SCHEMBL15109816 0.62 USP30 (0.43) LMNASMN1; SMN2CYP1A1DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076327-B2 Condensed imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2011-12-13 — — US disclosed
US-8076327-B2 Condensed imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2011-12-13 — — US disclosed
US-8076327-B2 Condensed imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2011-12-13 — — US disclosed
US-20100305110-A1 CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2010-12-02 — — US disclosed
US-20100305110-A1 CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2010-12-02 — — US disclosed
US-20100305110-A1 CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2010-12-02 — — US disclosed
US-7799780-B2 Condensed imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2010-09-21 — — US disclosed
US-7799780-B2 Condensed imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2010-09-21 — — US disclosed
US-7799780-B2 Condensed imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2010-09-21 — — US disclosed
US-7795253-B2 Condensed imidazole derivatives as aromatase inhibitors NOVARTIS AG (CH) 2010-09-14 — — US disclosed
US-7795253-B2 Condensed imidazole derivatives as aromatase inhibitors NOVARTIS AG (CH) 2010-09-14 — — US disclosed
US-7795253-B2 Condensed imidazole derivatives as aromatase inhibitors NOVARTIS AG (CH) 2010-09-14 — — US disclosed
EP-2004657-B1 CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2010-09-01 — — EP disclosed
US-20090048241-A1 Condensed Imidazole Derivatives as Aromatase Inhibitors SPEEDEL EXPERIMENTA AG (CH) 2009-02-19 — — US disclosed
US-20090048241-A1 Condensed Imidazole Derivatives as Aromatase Inhibitors SPEEDEL EXPERIMENTA AG (CH) 2009-02-19 — — US disclosed
US-20090048241-A1 Condensed Imidazole Derivatives as Aromatase Inhibitors SPEEDEL EXPERIMENTA AG (CH) 2009-02-19 — — US disclosed
US-20090012068-A1 Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors NOVARTIS AG (CH) 2009-01-08 — — US disclosed
US-20090012068-A1 Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors NOVARTIS AG (CH) 2009-01-08 — — US disclosed
US-20090012068-A1 Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors NOVARTIS AG (CH) 2009-01-08 — — US disclosed
WO-2007116097-A1 CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012068-A1 Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors CYP11B1, CYP11B2, REN CYP17A1 6/4885CYP19A1 51/4885RIPK1 4065/4885
US-20100305110-A1 CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS CYP11B1, CYP11B2, REN CYP17A1 6/4885CYP19A1 50/4885RIPK1 4081/4885
US-20090048241-A1 Condensed Imidazole Derivatives as Aromatase Inhibitors CYP19A1, HSD17B11, ESR1 CYP17A1 5/4885CYP19A1 1/4885RIPK1 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.